Gilead Sciences delivers strong 2025 earnings, plans new cancer and HIV treatments

Gilead Sciences reported strong fourth-quarter and full-year 2025 financial results, with revenue exceeding expectations and a slight increase in total product sales, indicating growth in its core business despite competitive pressures.